STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.

Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue.

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $50.

Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy. Analyst Price Forecast Suggests 29.26% Upside As of December ...

Collegium Pharmaceutical Stock Down 0.3 % Shares of Collegium Pharmaceutical stock opened at $33.35 on Monday. Collegium Pharmaceutical, Inc. has a twelve month low of $28.39 and a twelve month ...

Collegium Pharmaceutical forecasts 2025 product revenues of $735-$750 million, with adjusted EBITDA of $435-$450 million. Collegium Pharmaceutical, Inc. has provided its financial guidance for ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL)). Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price target of $46.00. Discover outperforming stocks and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. "In 2024, we executed on our ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...